QC
KLRS

Quadrature Capital’s Kalaris Therapeutics KLRS Stock Holding History

Quadrature Capital’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.3K Buy
+16,527
New +$85.8K ﹤0.01% 1501

Other funds holding KLRS

WT
WHI Trust Chicago, Illinois $155M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
FCA
Fortis Capital Advisors Prairie Village, Kansas $889M AUM 36.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WAM
WealthTrust Asset Management Destin, Florida $185M AUM 26.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SFCL
Strengthening Families & Communities LLC Boston, Massachusetts $450M AUM 41.19% 1-Year Est. Return

Quadrature Capital's KLRS Position: Q2 2026 in Review

Quadrature Capital opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 16,527 shares worth $67.3K. The stake represents ﹤0.01% of the portfolio and ranks #1501 among its holdings.

14 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Quadrature Capital held 16,527 shares of Kalaris Therapeutics worth $67.3K as of Q2 2026.
  • Kalaris Therapeutics was a new Quadrature Capital position in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1501 holding.
  • 14 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.